China lashes out, new Obamacare competition, and a looming tax crackdown because this is where the money is.

Hi fools, welcome to the Wednesday Health Care Edition of Where the Money is.

We're happy to be back here with you.

I'm joined as usual by my fellow health care analyst in arms, Michael Douglas, Michael

how are you doing today?

Fantastic.

Lots of news.

There's a fair amount of news, although we are sort of entering that dry spell right before

earning season.

I can't wait for earnings to get going next month.

Oh yeah, we will have no sort of things to talk about that.

But we do have, we have some sort of bigger news, less company specific stuff.

We do have a deal that we'll cover at the end of the show.

But let's start with China. We know Glaxo Smith Clines had a ton of problems over there.

They finally ended their bribery probe over there. Glaxo is going to get fined almost

$500,, $498 million.

What's your take on this?

You know, it's good that this is finally done.

Of course, not a good thing that this is an enormous fine, but it's good for

Glaxo to have this behind it so it can so the company can kind of focus on, you know,

first up growing the pipeline and then also trying to sort of build back its commercialization

presence in China.

...